Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the same

1. A method of therapeutically treating infertility in a human patient, said method comprising administering to said patient a therapeutically effective amount of crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, wherein said crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl) carbonyl]pyrrolidin-3-one O-methyloxime exhibits characteristic peaks at diffraction angle 2-theta degrees appearing at least at about 7.05, about 12.25, and about 18.00, as measured by X-ray powder diffraction (XRPD).

2. The method of claim 1 , wherein said patient is undergoing embryo transfer, and whereby said administering reduces the likelihood of embryo implantation failure in said patient.

3. The method of claim 2 , wherein said embryo transfer comprises in vitro fertilization (IVF) thereby producing one or more embryos, followed by transfer of said one or more embryos to said patient.

4. The method of claim 1 , wherein said crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl) carbonyl]pyrrolidin-3-one O-methyloxime is characterized by an XRPD pattern substantially as illustrated in FIG. 1 .

5. The method of claim 1 , wherein said crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl) carbonyl]pyrrolidin-3-one O-methyloxime exhibits characteristic peaks at diffraction angle 2-theta degrees appearing at least at about 23.34, about 13.13, and about 7.05, as measured by XRPD.

6. The method of claim 1 , wherein said crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl) carbonyl]pyrrolidin-3-one O-methyloxime is characterized by a differential scanning calorimetry (DSC) curve substantially as illustrated in FIG. 6 or FIG. 7 .

7. The method of claim 1 , wherein said crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl) carbonyl]pyrrolidin-3-one O-methyloxime is characterized by a thermo-gravimetric analysis (TGA) curve substantially as illustrated in FIG. 8 or FIG. 9 .

8. The method of claim 1 , said method comprising administering said crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl) carbonyl]pyrrolidin-3-one O-methyloxime to said patient in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients.

9. A method of increasing embryo implantation rate in a human patient undergoing embryo transfer, said method comprising administering to said patient a therapeutically effective amount of crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, wherein said crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl) carbonyl]pyrrolidin-3-one O-methyloxime exhibits characteristic peaks at diffraction angle 2-theta degrees appearing at least at about 7.05, about 12.25, and about 18.00, as measured by XRPD.

10. The method of claim 9 , wherein said embryo transfer comprises IVF thereby producing one or more embryos, followed by transfer of said one or more embryos to said patient.

11. The method of claim 9 , wherein said crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl) carbonyl]pyrrolidin-3-one O-methyloxime is characterized by an XRPD pattern substantially as illustrated in FIG. 1 .

12. The method of claim 9 , wherein said crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl) carbonyl]pyrrolidin-3-one O-methyloxime exhibits characteristic peaks at diffraction angle 2-theta degrees appearing at least at about 23.34, about 13.13, and about 7.05, as measured by XRPD.

13. The method of claim 9 , wherein said crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl) carbonyl]pyrrolidin-3-one O-methyloxime is characterized by a DSC curve substantially as illustrated in FIG. 6 or FIG. 7 .

14. The method of claim 9 , wherein said crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl) carbonyl]pyrrolidin-3-one O-methyloxime is characterized by a TGA curve substantially as illustrated in FIG. 8 or FIG. 9 .

15. The method of claim 9 , said method comprising administering said crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl) carbonyl]pyrrolidin-3-one O-methyloxime to said patient in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients.

16. The method of claim 1 , wherein the crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime has a purity over about 85% by weight.

17. The method of claim 16 , wherein the crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime has a purity over about 90% by weight.

18. The method of claim 17 , wherein the crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime has a purity over about 95% by weight.

19. The method of claim 18 , wherein the crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime has a purity over about 98% by weight.

20. The method of claim 9 , wherein the crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime has a purity over about 85% by weight.

21. The method of claim 20 , wherein the crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime has a purity over about 90% by weight.

22. The method of claim 21 , wherein the crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime has a purity over about 95% by weight.

23. The method of claim 22 , wherein the crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime has a purity over about 98% by weight.